A Democrat congressman seeks to codify Trump’s revolutionary drug pricing order while Republican leaders remain strangely silent on an initiative that could save American lives and money.
At a Glance
- Democrat Rep. Ro Khanna introduced legislation to codify President Trump’s executive order on reducing prescription drug prices
- Trump’s “Most Favored Nation” pricing policy could reduce U.S. drug costs by 30% to 80%
- Khanna seeks bipartisan support, emphasizing the choice between supporting Big Pharma or American consumers
- GOP-controlled Congress faces criticism for not supporting Trump’s agenda on drug pricing
- Some Republican senators openly opposed Trump’s plan during a Senate hearing
Democrat Takes Lead on Trump’s Drug Pricing Initiative
In a surprising political development, Democrat Representative Ro Khanna has introduced legislation to codify President Trump’s recent executive order on prescription drug pricing. The California congressman’s bill would permanently establish the “Most Favored Nation” pricing system for pharmaceuticals that President Trump enacted by executive order on May 14, 2025.
This system would require pharmaceutical companies to offer Americans the same lower prices they offer to citizens in other developed nations, potentially slashing drug costs for U.S. consumers by 30% to 80% across the board.
President Trump has described this executive order as “one of the most important and consequential” in American history, directly addressing a critical concern for millions of Americans who struggle to afford necessary medications.
The unprecedented move has widespread support among voters across the political spectrum who have long complained about paying substantially more for the exact same prescription drugs than patients in other countries.
SHAME ON GOP HOUSE: Democrat Ro Khanna Files Bill to Codify Trump’s Drug Price Order — While Republican Leadership Sits on Their Hands https://t.co/gEYmgOnBuh
— Steve Ferguson (@lsferguson) May 14, 2025
A Call for Bipartisan Cooperation
Rep. Khanna has publicly called for Republican co-sponsors to join his legislation, framing the issue as a clear choice between supporting everyday Americans or pharmaceutical industry interests. “This is a moment of truth for Republicans in Congress,” Khanna stated. “Will they stand with President Trump and the American people, or with Big Pharma?” The congressman’s appeal for bipartisan support highlights how drug pricing reform transcends traditional party lines, focusing instead on addressing a critical pocketbook issue for American families.
The Democrat’s move to champion a key Trump initiative comes at a time when the GOP-controlled Congress faces mounting criticism for its legislative ineffectiveness. According to reports, the current Republican-led Congress has sent fewer bills to President Trump’s desk than any Congress in the past 70 years, raising questions about Republican lawmakers’ commitment to advancing the president’s agenda despite controlling both chambers.
Republican Resistance Raises Questions
While President Trump has made lowering drug prices a centerpiece of his administration’s healthcare policy, some Republican senators have openly opposed the measure. During a recent Senate hearing, GOP members including Senator Thom Tillis and Senate Majority Leader John Thune expressed reservations about the pricing policy. Their opposition has sparked controversy among Trump supporters who question why Republican leadership appears reluctant to support a popular Trump initiative that could substantially reduce healthcare costs for their constituents.
Healthcare advocates point out that Americans pay significantly more for prescription medications than citizens of other developed nations, often for identical drugs manufactured by the same companies. The pharmaceutical industry has long maintained that higher U.S. prices are necessary to fund research and development, but critics argue that Americans shouldn’t bear a disproportionate share of these costs while pharmaceutical companies report record profits.
A Test of Political Priorities
As Khanna’s bill moves forward, it presents a clear political test for congressional Republicans. Will they support President Trump’s signature healthcare initiative, or will pharmaceutical industry influence prevail? The legislation offers Republican lawmakers an opportunity to demonstrate their commitment to both the president’s agenda and to addressing a key pocketbook issue for American families. How GOP leadership responds could significantly impact both healthcare access for millions of Americans and voter perceptions heading into future elections.
